Do Alzheimer’s Drugs Really Prolong Independence?

• 💊 Lecanemab and donanemab extend independence by 10 and 8 months, respectively, for early-stage Alzheimer’s patients.
• ⚠️ Both drugs carry risks, including brain swelling, microbleeds, and high financial costs.
• 🧠 Neither drug cures Alzheimer’s, but they slow the progression in the early stages.
• 🏥 Early diagnosis is crucial, as these treatments ineffective in moderate or late stages.
• 🔬 Future research may focus on personalized therapies and drugs that halt or reverse cognitive decline.

Do Alzheimer’s Drugs Really Prolong Independence?

Alzheimer’s disease is a progressive neurodegenerative disorder that gradually deteriorates memory, cognitive abilities, and the capacity for independent living. In recent years, two FDA-approved drugs—lecanemab (Leqembi) and **donanemab (Kisunla)**—have been developed to target amyloid beta plaques, a hallmark of Alzheimer’s disease. While they do not cure the condition, recent research suggests that they can moderately extend the period of independent living. A study from Washington University School of Medicine indicates that these medications could add several months to a patient’s ability to care for themselves, but they also come with significant risks and limitations.

Advertisement

How Lecanemab and Donanemab Work

Targeting Amyloid Beta Plaques

Both lecanemab and donanemab belong to a class of drugs known as monoclonal antibodies, designed to target amyloid beta plaques that accumulate in the brains of Alzheimer’s patients. These plaques are believed to disrupt neural communication, leading to cognitive decline. By reducing the buildup of these proteins, the drugs aim to slow, though not halt or reverse, disease progression.

Mechanism of Action

1. Lecanemab: Targets soluble protofibrils, which are early-stage clumps of amyloid beta that eventually form plaques. By attacking these before they solidify into harmful structures, the drug aims to reduce cognitive impairment.
2. Donanemab: Directly identifies and binds to deposited amyloid plaques, helping the immune system clear them. This approach helps lower existing plaque levels but does not address precursor formations as lecanemab does.

Who Can Take These Drugs?

Importantly, both lecanemab and donanemab are only approved for early-stage Alzheimer’s patients. Evidence suggests that once Alzheimer’s disease progresses into moderate or severe stages, these medications provide no meaningful benefit.

Study Findings: Do These Drugs Truly Extend Independence?

A groundbreaking study published in the Alzheimer’s Association Journal tracked 282 patients receiving either lecanemab or donanemab in early-stage Alzheimer’s and found:

• Without medical intervention, patients maintained independence for 29 months on average.
• With lecanemab, independence extended to 39 months (10 additional months).
• With donanemab, independence extended to 37 months (8 additional months).

What Does This Mean for Patients?

These findings suggest that lecanemab and donanemab can slow functional decline, offering patients more time to live without full-time care. While not a dramatic extension, an additional 8-10 months of independence can be crucial for both patients and caregivers.

However, the real-world impact varies based on individual health, genetic predisposition, and adherence to treatment. Some patients may see greater benefits, while others may experience minimal improvement or severe side effects.

Benefits of Lecanemab and Donanemab

Given the limitations of Alzheimer’s treatments, even modest improvements in functionality can be valuable. The primary benefits of these drugs include:

🚀 Slowing Functional Decline

Patients taking lecanemab or donanemab demonstrate delayed loss of cognitive and motor abilities, allowing them to engage in daily activities longer.

⏳ More Time for Early-Stage Independence

Early-stage Alzheimer’s is when individuals remain most autonomous—these drugs extend this period, allowing patients to live at home rather than transitioning to assisted care too soon.

❤️ Less Caregiver Burden

Extended independent living gives families and caregivers more time before taking on full-time care responsibilities. This can reduce stress and emotional strain on loved ones.

🏡 Better Planning for Long-Term Care

Patients and families gain additional time to plan for future transitions, including financial arrangements, legal decisions, and living accommodations.

Risks and Potential Side Effects

Despite the potential upside, these drugs carry significant risks, particularly related to brain health and financial burden.

⚠️ Medical Risks

• Brain Swelling (ARIA-E) – Some patients experience a condition called Amyloid-Related Imaging Abnormalities (ARIA), which can cause brain swelling and, in severe cases, lead to neurological complications.
• Microbleeds (ARIA-H) – Small brain hemorrhages have been reported, posing additional risks, especially for those on anticoagulants.
• Mild to Severe Headaches – Some patients report headaches and dizziness, particularly after the initial doses.

💰 Financial Costs and Accessibility

• High Price Tags – These drugs can cost tens of thousands of dollars annually, and insurance coverage is limited.
• Not Widely Accessible – These treatments require specialized administration, consistent monitoring, and frequent imaging scans, limiting accessibility to patients who live near major medical centers.

⏳ Limited Long-Term Effectiveness

• While beneficial in early-stage patients, neither drug stops Alzheimer’s progression beyond a certain point.
• Patients will still develop severe Alzheimer’s symptoms, meaning these drugs primarily delay rather than prevent cognitive decline.

Study Limitations and Considerations

While the Washington University study presents promising findings, several limitations should be noted:

1. Highly Educated and Research-Savvy Participants
   • Many study participants were highly engaged in Alzheimer’s research, received optimal care, and had strong social support systems—factors not always present in the general population.
2. Short-Term Data
   • Findings are limited to a few years of observation; long-term effects remain uncertain.
3. Financial Access Not Considered

• The study does not account for cost barriers to treatment, which may limit real-world applicability.

Expert Perspectives on Findings

Leading experts in neurology and geriatrics have weighed in on these results:

• Dr. Sarah Hartz, Washington University Medicine – Calls the findings “clinically meaningful” but warns that treatment access remains a barrier.
• Christopher Weber, Alzheimer’s Association – Stresses the importance of early diagnosis and active treatment to maximize benefits.
• Dr. Chris Vercammen, Internal Medicine & Geriatrics – Believes that while these drugs extend independence, they do not alter the ultimate progression of the disease.

The Future of Alzheimer’s Treatments

Current research aims to go beyond amyloid targeting and explore alternative therapeutic strategies:

🔬 New Drug Development

Scientists are investigating other biological pathways, including tau protein inhibitors and neuroinflammation reduction treatments.

🧑‍⚕️ Personalized Medicine

Future treatments may incorporate genetic testing and biomarker assessments to tailor therapies to individuals, maximizing effectiveness.

🏋️‍♂️ Lifestyle and Non-Drug Interventions

Integration of diet, exercise, and cognitive stimulation therapies could further improve patient outcomes.

What Should Patients and Families Consider?

Before pursuing lecanemab or donanemab, families should:

• 📋 Discuss risks with doctors, considering side effects and eligibility.
• 💰 Assess financial costs, including insurance coverage and out-of-pocket expenses.
• 🔍 Set realistic expectations—these drugs slow decline but do not cure Alzheimer’s.
• 🏡 Plan for later-stage care, including assisted living or in-home support.

The latest research underscores that lecanemab and donanemab can provide several additional months of functional independence for early-stage Alzheimer’s patients. While this can significantly impact quality of life, these treatments come with substantial risks, costs, and limitations. Patients and caregivers should have thorough discussions with medical professionals to weigh the benefits against the drawbacks, ensuring informed decision-making.